Get started
Author

Lutz Achtnichts

Observed name: Achtnichts, Lutz
Institution: Kantonsspital Aarau
ORCID: 0000-0002-3713-9570
Observed ORCID: 0000-0002-3713-9570
OpenAlex ID: A5103143563
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
2018 · Ludwig Kappos, Amit Bar-Or, et al. · The Lancet · 983
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
2021 · Lutz Achtnichts, Barbara Jakopp, et al. · Vaccines · 41
PDF
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis
2024 · Johanna Oechtering, Kerstin Stein, et al. · Neurology Neuroimmunology & Neuroinflammation · 39
PDF
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis
2025 · Johanna Oechtering, Sabine Anna Schaedelin, et al. · Neurology Neuroimmunology & Neuroinflammation · 23
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
2022 · Lutz Achtnichts, Arkady Ovchinnikov, et al. · Vaccines · 12
PDF
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity
2025 · Sofia Sandgren, Aleksandra Maleska Maceski, et al. · Multiple Sclerosis Journal · 6
Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022
2022 · Christoph Friedli, Anke Salmen, et al. · Clinical and Translational Neuroscience · 4
PDF
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis Cohort
2025 · Maximilian Einsiedler, Chiara Zecca, et al. · Neurology Clinical Practice · 3
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort
2025 · Giulio Disanto, Sabine Schaedelin, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 1
Particularités de l’immunothérapie de la sclérose en plaques en Suisse: mise à jour
2024 · Christoph Friedli, Anke Salmen, et al. · Forum Médical Suisse ‒ Swiss Medical Forum · 1
PDF
Besonderheiten der Immuntherapie der Multiplen Sklerose in der Schweiz: Update
2024 · Christoph Friedli, Anke Salmen, et al. · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · 1
PDF
Besonderheiten der Immuntherapie der Multiplen Sklerose in der Schweiz
2019 · Lutz Achtnichts, Andrew Chan, et al. · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · 1
PDF
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis
2025 · Abdelhak, Ahmed, Bachhuber, Franziska, et al. · Zurich Open Repository and Archive (University of Zurich)
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity
2025 · Sandgren, Sofia, Maleska Maceski, Aleksandra, et al. · Zurich Open Repository and Archive (University of Zurich)
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study
2025 · Yaldizli, Özgür, Benkert, Pascal, et al. · Zurich Open Repository and Archive (University of Zurich)
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort
2025 · Disanto, Giulio, Schaedelin, Sabine, et al. · Zurich Open Repository and Archive (University of Zurich)
Works count: 16
Citation count: 1,115
H-index: 6
I10-index: 5
Year
Topic
Type